• Ozguc Takmaz, Ercan Bastu, Esra Ozbasli, Savas Gundogan, Emine Karabuk, Muharrem Kocyigit, Suat Dede, Murat Naki, Faruk Kose, and Mete Gungor.
• Department of Obstetrics and Gynecology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey (Drs. Takmaz, Bastu, Ozbasli, Gundogan, Karabuk, Dede, Naki, Kose, and Gungor).
• J Minim Invasive Gynecol. 2020 Mar 1; 27 (3): 665-672.

Study ObjectiveTo evaluate the effect of perioperative duloxetine on pain management in patients recovering from laparoscopic hysterectomy.DesignA randomized placebo-controlled trial.SettingA university hospital.PatientsOf 100 patients enrolled, 80 were randomized 1:1 to receive perioperative duloxetine (n = 40) or placebo (n = 40).InterventionsPatients undergoing laparoscopic hysterectomy for benign conditions from November 2017 through March 2018 received 2 doses of 60 mg duloxetine or placebo 2 hours before and 24 hours after surgery.Measurements And Main ResultsThe Quality of Recovery (QoR)-40 questionnaire was completed by participants after discharge. Study and control groups were compared in terms of questionnaire scores, opioid analgesic use, and hospital length of stay. The baseline characteristics of the groups were comparable; median total QoR-40 scores were 111 of 200 and 112 of 200 for duloxetine and the placebo group, respectively; the difference did not reach statistical significance (p = .91). Although the physical independence subcomponent of the recovery questionnaire was improved in favor of duloxetine, none of the subcomponents reached statistical difference between groups. The groups did not differ in terms of postoperative narcotic analgesic use and hospital length of stay (p >.05).ConclusionPerioperative duloxetine did not reduce pain, need for narcotic analgesia, or hospital length of stay following laparoscopic hysterectomy.Copyright © 2019 AAGL. Published by Elsevier Inc. All rights reserved.

36 keywords...

hide…